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Abstract
Background: Previous studies from our group demonstrated the anti-inflammatory properties of statins on cardiopulmonary
bypass (CPB), through inhibition of neutrophil transendothelial migration. We sought to determine the utility of preoperative
statin on patients undergoing cardiac surgery, to investigate any moderating effects on the systemic inflammatory response
(SIRS) with CPB, and to evaluate any clinical impact on our patients.
Methods: This is a prospective, randomised controlled trial with national regulatory body approval. Eligible
patients were already on oral statin therapy. They were then randomly assigned to either investigation arm (n = 15,
atorvastatin 80 mg for 2 weeks before surgery) or control arm (n = 15, no change to current statin therapy). Blood and
urine samples were collected at 3 timepoints. Postoperative clinical measures were documented.
Results: Patients in the investigation arm have significantly lower troponin level (p = 0.016), and lower level of
urine neutrophil gelatinase-associated lipocalin (NGAL; p = 0.002); thus demonstrating a lesser degree of cardiac and renal
injury in these patients. Higher level of Interleukin-8 (IL-8) at baseline (p = 0.036) and 4 h post cross-clamp
removal (p = 0.035) in the investiation arm. A similar trend is also observed in Matrix Metalloproteinase-9 (MMP-9;
p > 0.05). There were however no differences in clinical outcomes.
Conclusions: Maximizing the dose of statin in patients waiting for cardiac surgery has measurable biological effects.
There is evidence of less cardiac and renal damage. The use of preoperative statins and in particular, high dose
preoperative statin therapy, may prove a useful new tool for optimal preparation of patients for cardiac surgery.
Trial registration: EudraCT no. 2012-003396-20. Registered 05 November 2012
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Background
Cardiac surgery is known to provoke a vigorous inflam-
matory response. This is at least attributable to the use
of cardiopulmonary bypass (CPB). The mechanisms by
which CPB activates the inflammatory response included
the direct ‘contact activation of the immune system
following blood contact with the foreign surface of the
apparatus, ischaemic-reperfusion injury [1] and the pres-
ence of endotoxaemia [2, 3]. These lead to the increase
in humoral and cellular response, which ultimately leads
to the development of systemic inflammatory response
(SIRS). Once initiated, the SIRS is maintained by a num-
ber of proinflammatory mediators including interleukin-
1 (IL-1), interleukin-2 (IL-2), interleukin-6 (IL-6),
interleukin-8 (IL-8) and tumor necrosis factor-alpha
(TNF-α) [4]. These in turn, facilitate the activation of
neutrophil. The activated neutrophils release reactive
oxygen species (ROS), causing damage to cellular mem-
branes, stimulate leukocyte activation, chemotaxis and
leukocyte-endohelial adherence [5]. These activated
neutrophils, once migrated beyond the basement mem-
brane through to the extracellular matrix (ECM) to the
point of insult, will ultimately leads to tissue damage
and multiple organ dysfunction. The development and
use of new strategies aimed at prophylactically attenuate
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the systemic inflammatory response, and reducing post-
operative morbidity following cardiopulmonary bypass
related surgery, is of great importance.
Statin, a selective, competitive inhibitor of HMG-CoA
reductase (3-hydroxy-3-methyl-glutaryl-CoA reductase),
is recognised for its cholesterol lowering abilities. The
use of statin is indicated in patients with hypercholester-
olaemia as well as primary and secondary prevention of
cardiovascular disease. There are, however, increasing
evidences to suggest that statin also exerts a choleterol-
independent, anti-inflammatory property [6]. The ‘pleio-
morphic’ effects of statins have been reported in numerous
acute and chronic inflammatory diseases [7, 8].
Previous in vivo and in vitro works from our group
highlighted the protective properties of statin against
inflammation. We showed that statins alter neutrophil
migration via the Rho pathway [9], and further demon-
strated the impact of high-dose statin therapy (≥40 mg)
in transendothelial neutrophil migration [10]. In our
recent in vivo study, we identified that high-dose statin
(≥40 mg) attenuates MMP-9 production in the setting of
CPB associated surgery. As yet, however, our studies
have not shown a clinical benefit in patient outcomes.
The defined clinical endpoints such as duration on
mechanical ventilation, length of ITU and hospital stay
are heavily influenced by external factors such as indi-
vidual clinical practice, the availability of convalescence
facility to facilitate patient discharge. It is therefore
difficult to attribute any true meaning to any observed
difference between patient groups.
This study aims to assess the optimal dose of pre-
operative statin therapy in reducing end-organ injury
and improved clinical outcome post CPB. CPB serves as
an ideal model for analysis of ischemic-reperfusion
injury as there is a definite start and end point. The
cytokines chosen for this study have all been shown in
previous studies to have an adverse effect on end-
organ injury. By using more organ specific markers of
injury, we aim to discover more subtle differences
between our patient groups, which are less influenced
by external factors.
Methods
This prospective study included 30 patients who under-
went CPB related surgery from March 2013 to May
2014 at the Mater Misericordiae University Hospital.
The study protocol was approved by the Irish Medicine
Board (IMB) and hospital ethics committee. Informed
consent was obtained from each of the patients. We
included patients who underwent elective surgery.
Eligible patients were already on a statin therapy
(dose ≤ 40 mg). Patients are either on Atorvastatin or
Simvastatin as these are the two most commonly used sta-
tin therapy in our practice and both are similar in the
molecular structure and efficacy. We excluded those on
Rosuvastatin due to the differences in its potency as
compared to Atorvastatin and Simvastatin. We excluded
patients who had undergone emergency surgery, revision
surgery, use of an intra-aortic balloon pump (IABP)
preoperatively; patients with underlying infection disease
or other significant disease such as chronic inflammatory
disease, chronic liver disease, chronic kidney disease and
malignancy; patients who were being treated with cortico-
steroids or anti-inflammatory or immunosuppresants. We
performed a power analysis after the initial 10 patients
were recruited. This demonstrated a total number of 30
patients (15 in each arm) were needed to adequately
power the IL-8 and MMP-9 analysis. A clinical end-point
was not chosen, as it would involve a large number of
patients, which would require multicentre perhaps inter-
national cooperation. Our purpose is to lay the ground-
work for such a study.
The 30 patients included in the study were random-
ized into 2 study arms: control arm (n = 15) which
constituted patients who would continue their initial
statin therapy (≤40 mg); and an investigation arm
(n = 15) composed of patients who received atorvastatin
80 mg for at least 2 weeks before surgery. The block
randomization is done using random allocation cards
placed in a sealed envelope generated by an independent
person unrelated to the study, picked by the investigator,
to reveal the study arm in which the participant is allo-
cated to. The duration of 2 weeks at which patients in the
investigation arm received atorvastatin 80 mg is based
upon our previous study, which demonstrated that
neutrophil migration is attenuated following 2 weeks
exposure of high-dose statin [10]. After surgery, these pa-
tients would return to their initial dosage of statin therapy.
Surgical procedure and postoperative care
Patients undergoing cardiac surgery had a consistent
anesthetic technique (propofol, fentanyl, pancuronium).
Standard monitoring techniques (electrocardiogram,
central venous and arterial catheter, urinary catheter,
temperature probes) were used in all these patients. No
patient received steroids before or during the operation.
All operations were performed through a median
sternotomy. Sodium heparin (300 U/kg) was adminis-
tered intravenously before CPB to achieve ACT ≥470 s.
Standard cannulation technique (cannulation of the
ascending aorta and the right atrium) was performed.
Standard CPB circuit was used in all patients. This
consists of a membrane oxygenator (Cobe, Cardiovascu-
lar, Sorin Biomedical, Gloucester, UK) and a roller pump
(Computer Assisted Perfusion System, CAPS, STÖKERT,
Sorin Biomedica, Gloucester, UK) primed with 1.0–1.2 l of
crystalloid solution. Similar myocardial protection strategy
was used in all. This consists of cold intermittent blood
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cardioplegia solution administered via the aortic root.
Mild hypothermia was induced with the heat exchanger of
the extracorporeal circuit and topical slush was used
concomitantly.
At the end of the surgical procedures, the patients
were transferred to the intensive care unit (ICU), where
they remained sedated with morphine and midazolam
(administered as needed). The patients remained intu-
bated and connected to a mechanical ventilator set in
synchronised intermittent mandatory ventilation (SIMV)
with tidal volume 6–10 ml/kg, respiratory rate 12
breaths/min; the positive end-expiratory pressure set
between 5 and 7 cm H2O; and fraction of inspired
oxygen adjusted according to arterial blood gas analysis.
The minimum mechanical ventilation time was 6 h; after
6 h, patients with stable haemodynamic, ventilation,
oxygenation, and temperature conditions were extu-
bated. Haemodynamic monitoring was maintained for at
least the first 24 h of the postoperative period.
Blood and urine sample collection, storage and analysis
White cell count, neutrophils and serum creatinine were
measured at baseline (before the surgical intervention)
and after surgery once the patients were stabilised.
Serum IL-8 and MMP-9 levels were determined in
arterial blood samples at the following time points: at
anaesthesia induction (reflecting patient’s baseline); 5 min
post cross-clamp removal (reflecting CPB activation and
reperfusion injury); 4 h post cross-clamp removal (reflect-
ing CPB activation and ischaemic-reperfusion injury).
Serum high-sensitive Cardiac Troponin (hs-cTnI) were
determined in arterial bloods samples at anesthesia induc-
tion and 4 h post cross-clamp removal. Neutrophil
gelatinase-associated lipocalin (NGAL) level were deter-
mined in urine samples at 4 h post cross-clamp removal.
The blood samples were collected via arterial line and
immediately centrifuged at 1500 rpm for 15 min and
stored at −80 °C until analysis. The urine samples were
collected via indwelling urinary catheter and immedi-
ately centrifuged at 4 °C and 4000 rpm for 10 min and
stored at −80 °C until analysis.
The IL-8 and MMP-9 were measured using the
Mesoscale Discovery (MSD®), Multi Array Assay, ultra-
sensitive kit (Maryland, USA), which is an enzyme-
linked immunosorbent assay in conjuction with the
MSD® SECTOR Imager SI 2400 automatic analyser. The
hs-cTnI was measured using the Architect STAT
Troponin-I assay (Abbott Diagnostics), which is a 2-step
chemiluminescent microparticle immunoassay, in con-
junction with the ARCHITECT iSystem optics ci8200.
The NGAL was measured using the ARCHITECT urine
NGAL assay (Abbott Diagnostics), which is a 2-step
chemiluminescent microparticle immunoassay, in con-
junction with the ARCHITECT iSystem optics ci8200.
Statistical analysis
Statistical analysis was performed using the statistical
software, SPSS 20.0 for windows. Each cytokine was
measured at 3 timepoints. Significant differences in
expression levels at each time point were examined
using a Friedman test. This is the non-parametric alter-
native to the parametric one-way repeated measures
analysis of variance (ANOVA) and was used due to the
non-normality of cytokine expression. If significant
differences were identified across time points using the
Friedman test, a post hoc Wilcoxon test was used to
identify which pairs of time point were significantly
different in terms of cytokine expression. At each time-
point, the average cytokine expression for the control
arm was compared to that of the investigation arm and
significant differences were testing using a Mann
Whitney U test. This is the non-parametric alternative
to independent samples t-test. A p value of <0.05 was
considered to be significant.
Results
Baseline patient characteristics
The clinical and operative characteristics were similar in
the investigation arm and the control arm. Only the
prevalence of diabetes were significantly higher in the
investigation arm (p = 0.032) (Table 1). Liver function
test at time of randomisation and after 2 weeks of treat-
ment were similar in both groups, and no side effects
were documented in patients (Table 2).
Postoperative patient course
The postoperative characteristics were similar between
both arms. There were no renal injury or mortality in
either group. There was a transient ischemic attack in
the control arm, in which the patient made a
complete recovery within 24 h after the onset of
symptom (Table 3).
Both groups have similar respiratory index ratio pre
extubation, however post extubation index was more
favourable in the investigation arm.
White cell count and neutrophil count
White cell count (WCC) and neutrophil count were
collected on admission to day 5 postoperatively.
Levels of WCC and neutrophil were elevated in both
arms postoperatively, peaked at day 2 post-operation
(Fig. 1). Level of WCC were higher in the investiga-
tion arm from baseline to day 5 postoperatively (p >
0.05) (Fig. 1a). Neutrophil counts were higher in the
investigation arm from baseline to day 2 postoperatively
but the patients in the control arm demonstrated
higher level of neutrophil on day 5 post-operation
(p > 0.05) (Fig. 1b).
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Interleukin-8 Levels
The serum IL-8 in the investigation arm was 11.2 +/−
1.8 pg/ml at baseline, vs. 8.6 +/− 1.0 pg/ml in the control
arm, p = 0.036. An increased in IL-8 production was
observed at 5 min after the release of the aortic cross-
clamp but not statistically significant. At 4 h, the serum
IL-8 in the investigation arm was 44.3 +/− 8.5 pg/ml vs.
28.3 +/− 4.3 pg/ml in the control arm, p = 0.035 (Fig. 2).
Matrix metalloproteinase 9 levels
The MMP-9 production was compared between both
amrs. There was no statistical significant (p = 0.520)
difference at any of the 3 time points between the two
groups (Fig. 3).
Level of serum creatinine
Serum creatinine levels were collected on admission
to day 5 postoperatively. Even though there was a
trend of lower level of serum creatinine noted in
the investigation arm, this is not statistically signifi-
cant (Fig. 4).
Level of urine neutrophil gelatine-associated lipocalin
(NGAL) postoperatively
Urine NGAL was measured in all patients postopera-
tively at 4 h post aortic cross-clamp removal. Urine
NGAL was 75.9 +/− 35.9 ng/ml in the control arm;
48.4 +/− 102.8 ng/ml in the investigation arm, p =
0.002 (Fig. 5).
Level of Troponin I
We analyzed the serum levels of hs-cTnI taken at two
different times. The baseline hs-cTnI was similar between
both groups (Fig. 6a). Hs-cTnI was 3516.1+/−465.2 pg/ml
in the control arm; 6380.6+/−1672.5 pg/ml in the investi-
gation arm, p = 0.016 (Fig. 6b). The hs-cTnIs were
Table 1 Baseline, clinical and operative parameters of patients





Age, year 64 (+/−2.1) 67 (+/−2.8) 0.442 N/S
Gender 0.152
Male 14 (93.3) 11 (73.3)
Female 1 (6.7) 4 (26.7)
Myocardial infarction 0.299
No 14 (93.3) 12 (80)
Yes 1 (6.7) 3 (20)
Diabetes mellitus 0.032
No 15 (100) 11 (73.3)
Yes 0 (0) 4 (26.7)
EF (%) 0.566
Good 9 (60) 11 (73.3)
Fair 5 (35) 3 (20)
Poor 1 (5) 1 (6.7)
Euroscore II, % 0.87 (+/− 0.35) 1.11 (+/− 0.18) 0.101 N/S
Procedure 0.863
CABG 11 (73.3) 10 (66.7)
Valve 0 (0) 1 (6.7)
Combined 2 (13.3) 4 (26.7)
Other 2 (13.3) 0 (0)
CPB time, mins 108 (+/−9.8) 117 (+/−7.1) 0.271 N/S
Aortic cross-clamp, mins 92 (+/−7.9) 97 (+/−6.9) 0.722 N/S
CABG Coronary artery bypass grafting, CPB Cardiopulmonary bypass, EF
Ejection fraction, N/S Not significant
Values are expressed as median (+/− SEM) or as number and percentage. P < 0.05
was considered statistically significant
Table 2 Comparison of liver function test at baseline and after






Liver function test (at baseline)
Bilirubin, μmol/l 11 ± 1.1 12 ± 2.1 0.153
ALP, IU/l 80 ± 6.4 75 ± 5.3 0.858
ALT, IU/l 36 ± 6.6 22 ± 4.8 0.806
γGT, IU/l 24 ± 11.4 24 ± 8.1 0.403
Liver function test (after treatment)
Bilirubin, μmol/l 10 ± 2.0 13 ± 2.7 0.916
ALP, IU/l 75 ± 5.0 87 ± 3.9 0.334
ALT, IU/l 26 ± 2.9 28 ± 3.8 0.676
γGT, IU/l 29 ± 6.1 23 ± 5.8 0.725
Side effects
Rhabdomyolysis 0 0 –
GI Disturbances 0 0 –
Renal Impairment 0 0 –
Table 3 Postopeative course of patients







14 (+/− 0.9) 15 (+/− 4.3) 0.193
PaO2/FiO2 (at extubation) 44.3 (+/− 3.3) 43.4 (+/− 3.3) 0.289
PaO2/FiO2 (post extubation) 35.9 (+/− 6.2) 28.9 (+/− 3.7) 0.167
ICU stay, hours 21 (+/− 5.6) 18 (+/− 4.0) 0.510
Hospital stay, days 7 (+/− 0.6) 7 (+/− 0.9) 0.543
Acue kidney injury 0 (0) 0 (0) N/A
Transient ischaemic attack 1 (6.7) 0 (0) 0.326
Mortality 0 (0) 0 (0) N/A
Mortality at 1 Year 0 (0) 0 (0) N/A
FiO2 Fraction of inspired oxygen, ICU Intensive care unit, PaO2 Partial pressure
of oxygen, N/S Not significant
Values are expressed as median (+/− SEM) or as number and percentage. P < 0.05
was considered statistically significant
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presented in two separate figures due to the vast differ-
ence in levels between the two timepoints.
Discussion
The trauma of cardiac surgery, the use of CPB and the
established ischemic-reperfusion injury, are responsible
for the exaggerated activation of SIRS and its sequelae.
The development of SIRS is due to an upregulation of
both humoral and cellular responses. While much
research has identified a wide variety of cytokines
responsible and possible mechanism, little success was
achieved in improving the clinical outcome associated
with SIRS. Although the current standard clinical prac-
tice is very much focused on multi-organ supportive
care in postoperative period, a preventative approach
would have advantages.
We first demonstrated that neutrophils, which are
thought to be primary mediator of SIRS, have potentially
greater roles in cardiac transplantation than previously
recognized, and suggested that blockade of the early
allograft neutrophil infiltration might prevent subse-
quent lymphocyte recruitment and attenuate rejection
[11]. Subsequently, the study showed that preoperative
CD11b expression assessment might enable preoperative
indication of patients who will mount an exaggerated
and damaging neutrophil response to cardiac surgery
[12]. We were then able to validate that the variation in
individual neutrophil response influence the outcome of
patients post cardiac surgery. These findings suggested
that inhibition of neutrophil function and migration may
be beneficial to improve clinical outcome [13].
There are increasing evidence that statins exert a
cholesterol-independent, cardioprotective action. The
‘pleiomorphic’ effect of statins has been described in
many acute or chronic inflammatory diseases such as
atherosclerosis [14], sickle cell disease [15], sepsis [8]. A
meta analysis of 91,491 patients following cardiac
surgery [16], concluded that pre-operative statin therapy
Fig. 1 White cell count and neutrophils count over time, at baseline pre-operatively to day 5 post cardiopulmonary bypass related surgery in both
the control arm (n = 15) and the investigation arm (n = 15) patients. a White cell count. b Neutrophil count. Markers indicate the median and error
bars indicate the standard error of the mean. There was no statistically significant difference between the two groups in white cell count and
neutrophil count
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exerts substantial clinical benefit on early postoperative
adverse outcomes. A separate systemic review [17]
showed that prophylactic statin therapy can decrease the
inflammatory response in patients undergoing CPB
related surgery. We therefore initiated studies to
evaluate the benefit of statin pre-treatment in attenu-
ating the SIRS in CPB related surgery. We have
focused however on the higher dose range. Indeed
the control arm in this study is comparable to the
treatment arm in other studies.
Maher et al. first demonstrated in an in vitro study,
that statins reduce neutrophil migration towards the
chemoattractant N-formyl-Methionine-Leucine-Phenyl-
alanine (fMLP), and showed that statins blunt the
neutrophil migration in a Rho dependent manner [9].
Kinsella et al. subsequently observed a difference in
Fig. 2 Effect of cardiac surgery with cardiopulmonary bypass on patient’s serum IL-8. Blood samples were collected from the patients preoperatively
(as baseline), 5 min, 4 h post cross-clamp removal in both the control arm (n = 15) and the investigation arm (n = 15). Columns indicate the median
and error bars indicate the standard error of the mean. There were statistically significant difference between the two groups at baseline, *p = 0.035
and at 4 h post cross-clamp removal, **p = 0.036
Fig. 3 Effect of cardiac surgery with cardiopulmonary bypass on patient’s serum MMP-9. Blood samples were collected from the patients preoperatively
(as baseline), 5 min, 4 h post cross-clamp removal in both the control arm (n= 15) and the investigation arm (n= 15). Columns indicate the median and
error bars indicate the standard error of mean. There was no statistically significant difference between the two groups
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neutrophil migration, serum cholesterol and LDL
level in healthy volunteers after two weeks of statin
therapy [10].
In comparison to many studies published where
patients were being classified as ‘with statin’ or ‘no
statin’, our studies instead, divided the patients into
doses of statin, i.e., high (≥40 mg) or low (<40 mg) dose
when investigating the anti-inflammatory endpoints. In
the observational study, we found that statins appeared
protective against cardiac and renal injury in a dose
dependent manner. We also showed that high-dose
statin is associated with decreased MMP-9 production
in patients undergoing CPB related surgery. While the
results were very promising, clinical outcomes remained
similar between both groups.
Recognizing the weaknesses of observational trials, we
embarked on this prospective, randomised controlled
trial. In this study, we showed that statin attenuates IL-8
production in a dose dependent manner; at 4 h post
release of aortic cross-clamp. Interestingly, we observed
a trend of higher neutrophil count in the investigation
arm over the first 2 days post-operatively in spite of the
Fig. 4 Effect of cardiac surgery with cardiopulmonary bypass on patient’s serum creatinine levels. Blood samples were collected from the patients
on admission to day 5 postoperatively in both the control arm (n = 15) and the investigation arm (n = 15). Markers indicate the median and error
bars indicate the standard error of the mean. There was no statistical significance noted between the two groups
Fig. 5 Effect of cardiac surgery with cardiopulmonary bypass on patient’s urine neutrophil gelatinase-associated lipocalin (NGAL). Urine samples
were collected from the patients at 4 h post release of aortic cross clam in both the control arm (n = 15) and the investigation arm (n = 15). Columns
indicate the median and error bars indicate the standard error of the mean. There were statistically significant difference between the two
groups, *p = 0.002
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lower IL-8 level. We proposed that this is probably due
to the result of statin in attenuating neutrophil migra-
tion, resulting in higher level of extracellular neutrophil.
In addition, we also demonstrated that statin is protect-
ive against end-organ injury as evident of a decreased
cardiac and renal injury with lower levels of Troponin I
and NGAL observed in the high-dose statin group.
Diagnosis of renal injury during CPB related surgery is
not established in a timely fashion until significant
damage has occurred. This is partly because of the lack
of a clinically available early biomarker. Serum creatinine
is used routinely in clinical practice, as it is the most
widely available marker to diagnose renal injury. It is
often not raised until >50% of renal function has already
been lost. This is common at 48 h after the initial insult
when the window period for early intervention is lost
[18]. In our study, we found no significant change in
patients’ serum creatinine from preoperative values to
day 5 postoperatively, in both groups of patients.
We further evaluate the extent of renal injury, using
urinary NGAL, a novel marker for renal injury. NGAL is
currently being applied in clinical studies and is showing
promising results [19]. NGAL can be detected as early
as 2 h after CPB [20], and a single measurement of
NGAL helps to distinguish acute kidney injury from
normal function, pre-renal azotemia and chronic kidney
Fig. 6 Effect of cardiac surgery with cardiopulmonary bypass on patient’s serum high sensitivity cardiac Troponin I (hs-cTnI) in both the control
arm (n = 15) and the investigation arm (n = 15). a At baseline. b At 4 h post release of aortic cross-clamp. Columns indicate the median and error
bars indicate the standard error of the mean. There were statistically significant difference between the two groups at 4 h post release of aortic
cross-clamp, *p = 0.016
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disease [21]. There was a significant difference between
patients in both groups of statin therapy at 4 h, which
has not been described previously.
We found no significant difference in terms of the
duration of mechanical ventilation, length of ITU or
hospital stay between the groups. However, we did
observe a trend of shorter duration of mechanical venti-
lation and length of ITU stay in the high-dose statin
group. We would suspect that if this were to be repeated
with higher numbers of patients we would reach
significance.
There are a number of strengths and weakness to our
study. Firstly, this is a prospective, randomised
controlled trial, which provided a Level 1 evidence [22].
This is clearly superior compared to our previous studies,
which are mostly observational, although we would also
acknowledge that the fundamental design of this random-
ized controlled trial is based upon the findings from the
previous studies. Secondly, other studies only compared
the groups with statin or no statin. Our study however
recruited patients who are already on a statin therapy,
before randomized patients into the control or investiga-
tion arm. If we indeed compare patients with no statin
versus high-dose statin therapy, a bigger effect might be
expected. However ethical considerations of depriving
patients of statins therapy completely prevented this. Our
sample size was small. As those who were randomized to
the investigation arm required a minimum of 2 weeks of
high-dose statin, this restricts the recruitment of partici-
pants to only the elective patients. In our centre, 65% of
the cardiac surgery performed in this time period was
classed as urgent or emergency.
Looking forward, we have established that optimizing
pre-operative statin therapy is associated with decreased
end-organ injury in patients undergoing surgery. The
ARMYDA-RECAPTURE trial, where 383 patients
undergoing PCI were randomized to atorvastatin reload
or placebo showed that reloading with high-dose atorva-
statin improved clinical outcome of patients on chronic
statin therapy undergoing PCI [23]. Additional studies
are required to determine if this shorter incubation time
will affect the immunological endpoints which we have
looked at, and to establish whether reload with high--
dose statin is associated with improved clinical outcome
in patients.
This study has established the benefit of high-dose
preoperative statin use in end-organ injury (cardiac and
renal) in patients undergoing CPB related surgery. The
inhibition of neutrophil migration is believed to be an
important factor related to the SIRS induced by CPB.
The use of statin, which is widely available at a relatively
low price, is certainly an appealing option in improving
patient outcome post CPB related surgery. This study
has laid the groundwork for future studies looking into
recruiting more patients with multicentre cooperation.
As practicing clinicians, we advocate the use of high-
dose preoperative statin therapy in patients undergoing
CPB related surgery. Some of our consultants have in-
deed started to give high dose statin therapy to their
patients scheduled to undergo CABG, while others have
yet to commit to this practice. As mentioned, our
continuous study is currently looking into determining if
the result is replicable when patient is given shorter
duration of high dose statin therapy, so that more
patients can be recruited into the study.
Conclusions
Maximizing the dose of statins in patients awaiting
cardiac surgery has measurable biological effects. There
is evidence of lesser cardiac and renal damage. The use
of preoperative statins and in particular, high dose
preoperative statin therapy, may prove a useful new tool
for optimal preparation of patients for cardiac surgery.
The research supports the routine use of statin therapy
in patients undergoing cardiac surgery and highlights
the specific importance of high dose statin therapy.
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